MarketBeat reports a USD 5.00 target for ADC Therapeutics stock

Published on 10/05/2026 at 03:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 19.25 million versus USD 18.89 million consensus. Six analysts cover ADC Therapeutics stock, with three Buy ratings.

ADCT, CH0499880968, Illustration mit AI erstellt.

ADC Therapeutics (CH0499880968) had a USD 5.00 average 12-month target on September 12, 2026, as MarketBeat reported. The target puts the analyst debate around the oncology biotech's pipeline and commercial product into a clearly quantified frame.

Second-quarter revenue beats consensus

MarketBeat said ADC Therapeutics generated USD 19.25 million in revenue in the second quarter of 2026, versus USD 18.89 million expected by analysts. The company also posted an adjusted loss of USD 0.11 per share, narrower than the USD 0.22 consensus loss.

The revenue comparison delivered a USD 0.36 million beat, while the adjusted loss was USD 0.11 per share better than consensus. That combination gives the latest reported quarter a stronger operating profile than the headline loss alone suggests.

Six analysts split on the outlook

According to MarketBeat on September 12, 2026, six brokerages covered ADC Therapeutics: three rated the stock Buy, two rated it Hold and one rated it Sell. The average recommendation was Hold, despite the USD 5.00 average target.

The split matters because it shows a wide gap between commercial execution and development risk. ADC Therapeutics is building around antibody-drug conjugates, with ZYNLONTA as its commercial product and clinical programs aimed at expanding treatment options in blood cancers.

Market value remains closely watched

ADC Therapeutics had a market capitalization of USD 136.0 million on September 12, 2026, while its 52-week range was USD 0.78 to USD 4.98. The company therefore remained valued below its annual high by USD 3.92, a market reference that keeps the USD 5.00 analyst target in a distinctly speculative framework.

For investors, the next assessment rests on whether revenue growth can continue while clinical and regulatory programs advance. The second-quarter revenue beat and narrower adjusted loss provide measurable progress, but the Hold consensus shows that analysts still weigh execution risk against the pipeline opportunity.

ADC Therapeutics stock valuation

ADC Therapeutics had a market capitalization of USD 136.0 million on the NYSE on September 12, 2026. Its 52-week range stood at USD 0.78 to USD 4.98, while the average analyst target was USD 5.00.